Korro Bio Inc. Ordinary Shares KRRO 深 滬
已收盤 08-01 16:00:00 美东时间
13.85
-1.110
-7.42%
華盛通- 最 高14.995
- 今 開14.95
- 成交量 14.40万股
- 最 低 13.34
- 昨 收 14.96
- 總市值 1.30亿
- 52周最高 98.00
- 市盈率 靜 --
- 換手率 1.53%
- 52周最低 10.29
- 委 比 -40.35%
- 總股本 939.05万
- 歷史最高 2918.50
- 量 比 1.50
- 振 幅 11.06%
- 歷史最低 9.15
- 每 手 1
- 風險率 14.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $100 price target.
07-24 18:11
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
<p>Korro Bio announced that its investigational medicine KRRO-110 has received orphan drug designation from the European Medicines Agency for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). This designation follows the U.S. FDA's orphan drug designation in March 2025. KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical study, with interim data expected in the second half of 2025. The medicine, designed to edit RNA and...
07-21 12:00
Novo Nordisk focused on biotech deals for cardiometabolic indications
In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has no plans to pursue deals with biotechs in other indications. "We want to be...
06-18 05:37
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 10.9% to $0.67 durin...
05-28 05:06
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
05-08 20:05
HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $100
HC Wainwright & Co. analyst Mitchell Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and lowers the price target from $115 to $100.
05-08 19:10
Korro Bio Announces Strategic Workforce Reduction Plan
Korro Bio ( ($KRRO) ) just unveiled an update. On May 7, 2025, Korro Bio announ...
05-08 05:24
美股大行评级 | 潜在涨幅195.08%！Absci获Keybanc升目标价至9美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119548656129204224.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Keybanc：维持Absci(ABSI)"超配"评级，目标价从5美元升至9美元</p> <p>• Keybanc：维持AbCellera Biologics(ABCL)"超配"评级，目标价从4美元升至5美元</p> <
04-17 08:46
